Dantrolene sodium: long-term effects in severe spasticity.
D000203:Activities of Daily Living; D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002547:Cerebral Palsy / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D003620:Dantrolene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D003975:Diazepam / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006827:Hydantoins / Q000627:therapeutic use*; D008297:Male; D008722:Methods; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D013035:Spasm / Q000188:drug therapy*; D013997:Time Factors
D006827:Hydantoins; D009125:Muscle Relaxants, Central; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D003620:Dantrolene; D003975:Diazepam